Partnering With Patient Advocacy Groups to Improve HS Awareness and Outcomes

Panelist discusses how patient advocacy groups act as critical bridges between patients, researchers, and health care providers, ultimately improving recognition, treatment, and quality of life for individuals affected by hidradenitis suppurativa.

EP: 1.Bridging the Gap in Recognizing Early Symptoms of Hidradenitis Suppurativa

EP: 2.Improving HS Diagnosis and Care Through Better Alignment of Staging and Severity

EP: 3.Addressing Social Determinants of Health in Hidradenitis Suppurativa Care

EP: 4.Economic Implications of Diagnostic Delays in Hidradenitis Suppurativa

EP: 5.Strategies for Equitable Access in Hidradenitis Suppurativa

Now Viewing

EP: 6.Partnering With Patient Advocacy Groups to Improve HS Awareness and Outcomes

EP: 7.Holistic Care for HS Patients: The Power of Multidisciplinary Models

EP: 8.The Case for HS Centers of Excellence: Evidence for Improved Patient Outcomes

EP: 9.Innovating HS Care: Applying Multidisciplinary Lessons to Diagnosis and Management

EP: 10.The Value Proposition: Justifying the Investment in HS Centers of Excellence

EP: 11.Key Takeaways on HS Care: Multidisciplinary Collaboration and Equity Solutions

EP: 12.Navigating HS Management: The Patient Journey

EP: 13.Advancing HS Outcomes: Resource Prioritization and Success Measurement

EP: 14.Tailoring HS Treatment: The Path to Better Patient Outcomes

Video content above is prompted by the following:

• Can you discuss the role of patient advocacy groups in promoting early recognition and comprehensive care for HS?
• Closing thoughts on HS for the AJMC viewing audience.

Related Videos

Related Content

Advertisement

May 12th 2025

For Patients Who Cannot Wait, This Off-the-Shelf CAR NK Treatment for AML Leaves Healthy Cells Alone

Stephen Strickland, MD, MSCI Interview by Mary Caffrey

First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research Institute. Strickland recently presented data from a phase 1 trial of SENTI-202, an investigational chimeric antigen receptor (CAR) natural killer (NK) cell therapy.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

May 9th 2025

New Evidence Links Arthritis to Increased Prostate Cancer Risk

Brooke McCormick

New research links arthritis to an increased risk of prostate cancer, highlighting the need for further studies on prevention and treatment strategies.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

May 9th 2025

Measles Cases Surge Amid Declining Vaccination Rates

Brooke McCormick

Measles cases surge in the US as vaccination rates decline, raising concerns about outbreaks and public health under Robert F. Kennedy Jr's leadership.

May 9th 2025

FDA Approves First Treatment for KRAS-Mutated Recurrent LGSOC

Brooke McCormick

FDA approves the first treatment for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC), offering new hope for patients with this condition.

Related Content

Advertisement

May 12th 2025

For Patients Who Cannot Wait, This Off-the-Shelf CAR NK Treatment for AML Leaves Healthy Cells Alone

Stephen Strickland, MD, MSCI Interview by Mary Caffrey

First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research Institute. Strickland recently presented data from a phase 1 trial of SENTI-202, an investigational chimeric antigen receptor (CAR) natural killer (NK) cell therapy.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

May 9th 2025

New Evidence Links Arthritis to Increased Prostate Cancer Risk

Brooke McCormick

New research links arthritis to an increased risk of prostate cancer, highlighting the need for further studies on prevention and treatment strategies.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

May 9th 2025

Measles Cases Surge Amid Declining Vaccination Rates

Brooke McCormick

Measles cases surge in the US as vaccination rates decline, raising concerns about outbreaks and public health under Robert F. Kennedy Jr's leadership.

May 9th 2025

FDA Approves First Treatment for KRAS-Mutated Recurrent LGSOC

Brooke McCormick

FDA approves the first treatment for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC), offering new hope for patients with this condition.